Company Overview
MacroGenics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to discovering, developing, manufacturing, and commercializing antibody-based therapeutics specifically for cancer treatment within the United States. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, a classification that defines its reliance on rigorous research and development cycles to bring novel molecular therapies to market. MacroGenics maintains a market capitalization of $201.47M, generates annual revenue of $149.50M, and employs a workforce of 293 individuals to execute its operational strategy. These financial figures indicate that the company holds a mid-cap profile with significant revenue generation relative to its employee base, suggesting a scalable operational model typical of established biotechnology firms that have moved beyond initial discovery phases into commercialization.
Financial Health
MacroGenics reported a total revenue of $149.50M over the trailing twelve months, yet it posted a net income of $-74,620,000 and an EBITDA of $-65,669,000, highlighting a substantial divergence between top-line sales and bottom-line profitability. The significant gap between the $149.50M revenue and the negative net income reveals a cost structure heavily influenced by research and development expenses or other operational costs that exceed gross profits, which is characteristic of clinical-stage development. The company generated a free cash flow of $-58,232,124, indicating a cash-burning operation that requires continuous capital infusion to sustain its pipeline and daily activities. Operating margins stand at -29.3%, gross margins are -22.5%, and profit margins are -49.9%; these negative figures collectively indicate that for every dollar of revenue generated, the company incurs more than a dollar in costs before reaching profitability. The balance sheet shows $189.91M in cash against $36.76M in debt, resulting in a debt-to-equity ratio of 66.13, which suggests the company is leveraged but maintains a robust cash reserve to cover its obligations. Additionally, the current ratio of 5.10 demonstrates strong short-term liquidity, implying the company possesses ample current assets to cover its current liabilities without immediate distress. Return on Equity is recorded at -86.9% and Return on Assets at -17.6%, metrics that reveal management has yet to generate positive returns on shareholder capital or the asset base, reflecting the early-stage nature of the business where reinvestment outweighs immediate earnings generation.
Valuation Assessment
MacroGenics presents a trailing P/E ratio of N/A due to its lack of positive earnings, while the forward P/E is listed at -3.27, a metric that implies the market is pricing in future earnings recovery or significant restructuring before positive earnings can be realized. The price-to-book ratio stands at 3.61, indicating that the market values the company at a significant premium over its net book value, likely driven by the perceived future value of its intangible assets and clinical pipeline. Alternative valuation metrics such as the price-to-sales ratio of 1.35 and an EV/EBITDA of -0.74 suggest the market is valuing the firm primarily on its revenue generation capabilities rather than current earnings power. The stock has traded between a 52-week low of $0.99 and a 52-week high of $3.54, placing the current valuation within a range that reflects high volatility often seen in biotechnology equities. The beta value of 1.39 indicates that the stock exhibits higher price volatility relative to the broader market, meaning it is expected to fluctuate more aggressively than the overall index during periods of market stress or rally.
Growth & Income
MacroGenics achieved a revenue growth rate of 113.0% year-over-year, while earnings growth is N/A, indicating that the company is in a phase where revenue expansion is outpacing any potential for earnings growth due to the absence of positive profits. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, instead choosing to reinvest all available resources into accelerating its product pipeline and expanding its therapeutic reach. The overall growth and income profile characterizes MacroGenics as a high-revenue-growth, non-yielding entity where shareholder value is created through capital appreciation and potential future profitability rather than current income distributions. The disparity between the massive revenue growth and the inability to generate positive earnings underscores the capital-intensive nature of developing antibody-based therapeutics for cancer treatment.